Filtered By:
Condition: Heart Failure
Drug: Coumadin
This page shows you your search results in order of date. This is page number 12.
Order by Relevance | Date
Total 289 results found since Jan 2013.
Clinical characteristics of hemodialysis patients with atrial fibrillation: The RAKUEN (Registry of atrial fibrillation in chronic kidney disease under hemodialysis from Niigata) study.
CONCLUSIONS: In our hemodialysis patients, AF was a common comorbidity and was independently associated with all-cause death and major bleeding, but not with increased risk of ischemic stroke.
PMID: 26527113 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - October 30, 2015 Category: Cardiology Authors: Mitsuma W, Matsubara T, Hatada K, Imai S, Saito N, Shimada H, Miyazaki S Tags: J Cardiol Source Type: research
Management of Atrial Fibrillation
Atrial fibrillation remains the most prevalent cardiac arrhythmia, and its incidence is increasing as the population ages. Common conditions associated with an increased incidence include advanced age, hypertension, heart failure, and valvular heart disease. Patients with atrial fibrillation may complain of palpitations, fatigue, and decreased exercise tolerance or may be completely asymptomatic. Options for treating patients who experience atrial fibrillation include rate-controlling drugs such as digoxin, β-blockers, and calcium channel blockers or a rhythm-controlling strategy with agents such as sodium channel blo...
Source: Journal of Intensive Care Medicine - October 29, 2015 Category: Intensive Care Authors: Zamani, P., Verdino, R. J. Tags: Analytic Reviews Source Type: research
Preventing Thrombosis to Improve Outcomes in Heart Failure Patients
Heart failure (HF) is associated with an increased risk of thrombotic events, particularly if this condition is accompanied by atrial fibrillation (AF). Many HF patients have background coronary artery disease (CAD) making them prone to coronary thrombosis resulting in myocardial infarction or sudden death. Oral anticoagulation is essential in the vast majority of HF patients with AF with non-vitamin K based anticoagulants being a suitable alternative to warfarin. In contrast, aspirin alone does not provide adequate stroke prevention in such patients.
Source: Progress in Cardiovascular Diseases - September 30, 2015 Category: Cardiology Authors: Eduard Shantsila, Gregory Y.H. Lip Source Type: research
Non‐vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta‐analysis of randomized trials
ConclusionAmong AF patients with HF, single‐/high‐dose NOAC regimens have a better efficacy and safety profile, but low‐dose regimens had similar efficacy and safety to warfarin. NOACs were similarly effective or even safer (less intracranial haemorrhage) in AF patients with HF compared with those without HF.
Source: European Journal of Heart Failure - September 3, 2015 Category: Cardiology Authors: Qinmei Xiong, Yee Cheng Lau, Keitaro Senoo, Deirdre A. Lane, Kui Hong, Gregory Y.H. Lip Tags: Original Article Source Type: research
Dabigatran for left ventricular thrombus.
Abstract
Male patient in dilated phase of hypertrophic cardiomyopathy had multiple hospitalizations during the past 2 years either due to congestive heart failure, stroke, scar epilepsy, or atrial fibrillation and ventricular tachycardia. Medication included evidence based therapy for heart failure, cordarone and warfarin. Anticoagulation had to be discontinued due to marked fluctuations in INR. Transthoracic Echocardiography (TTE) revealed a mobile mass in the left ventricle. He was treated with Dabigatran 110mg twice a day for 4 months without any bleeding or embolic episode and complete resolution of thrombus. ...
Source: Indian Heart J - September 1, 2015 Category: Cardiology Authors: Kolekar S, Munjewar C, Sharma S Tags: Indian Heart J Source Type: research
Use of Warfarin in Elderly Patients With Non-Valvular Atrial Fibrillation - Subanalysis of the J-RHYTHM Registry.
CONCLUSIONS: Warfarin could have beneficial effects even in very old NVAF patients if INR is kept between 1.6 and 2.59.
PMID: 26329097 [PubMed - as supplied by publisher]
Source: Circulation Journal - September 1, 2015 Category: Cardiology Authors: Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H, J-RHYTHM Registry Investigators Tags: Circ J Source Type: research
Residual Risk of Stroke and Death in Anticoagulated Patients According to the Type of Atrial Fibrillation: AMADEUS Trial Clinical Sciences
Conclusions—
The risk of cardiovascular death, stroke, or systemic embolism is higher in anticoagulated patients with permanent AF than in those with nonpermanent AF, regardless of preexisting heart failure.
Source: Stroke - August 24, 2015 Category: Neurology Authors: Senoo, K., Lip, G. Y. H., Lane, D. A., Buller, H. R., Kotecha, D. Tags: Thrombosis risk factors Clinical Sciences Source Type: research
One-Year Outcomes of Emergency Department Patients With Atrial Fibrillation: A Prospective, Multicenter Registry in China
There is lack of data about patient characteristics, practice patterns, and long-term adverse outcomes in patients with atrial fibrillation (AF) attending emergency departments (EDs) in China. A total of 2016 patients from 20 representative EDs were included. During 1 year, all-cause mortality was 291 (14.6%) cases, stroke/noncentral nervous system systemic embolism rate was 159 (8.0%) cases, and major bleeding was 26 (1.3%) cases. Heart failure, the major cause of mortality, accounted for 43.0% of deaths. Of 375 (18.6%) patients who used warfarin at baseline, only 217 (57.9%) patients were still on anticoagulation therapy...
Source: Angiology - August 12, 2015 Category: Cardiology Authors: Yang, Y.-M., Shao, X.-H., Zhu, J., Zhang, H., Liu, Y., Gao, X., Yu, L.-T., Liu, L.-S., Zhao, L., Yu, P.-F., Zhang, H., He, Q., Gu, X.-D. Tags: Atrial Fibrillation Source Type: research
Dabigatran for left ventricular thrombus
Publication date: Available online 8 August 2015 Source:Indian Heart Journal Author(s): Satishkumar Kolekar, Chandrashekhar Munjewar, Satyavan Sharma Male patient in dilated phase of hypertrophic cardiomyopathy had multiple hospitalizations during the past 2 years either due to congestive heart failure, stroke, scar epilepsy, or atrial fibrillation and ventricular tachycardia. Medication included evidence based therapy for heart failure, cordarone and warfarin. Anticoagulation had to be discontinued due to marked fluctuations in INR. Transthoracic Echocardiography (TTE) revealed a mobile mass in the left ventricle. He...
Source: Indian Heart Journal - August 8, 2015 Category: Cardiology Source Type: research
Underutilization of warfarin for stroke prophylaxis in patients with atrial fibrillation or atrial flutter in Korea.
CONCLUSIONS: A high portion of AF/AFL patients with CHADS2 score ≥2 were undertreated with warfarin. As ischemic stroke is one of the leading causes of death in Korea, a more aggressive approach to prevent stroke in patients with AF/AFL is required.
PMID: 26242197 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - August 1, 2015 Category: Cardiology Authors: Lee IH, Kim H, Je NK Tags: J Cardiol Source Type: research
Safety of Left Atrial Appendage Closure in Patients with Low Ejection Fraction
The Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation (PROTECT-AF) trial and subsequent Continued Access registry (CAP) compared left atrial appendage (LAA) closure with the Watchman device to continued warfarin anticoagulation for stroke prevention in patients with non-valvular atrial fibrillation (NVAF). Although the device was shown to have a high level of procedural safety across the entire trial population, safety of LAA closure in heart failure patients has not been assessed.
Source: Journal of Cardiac Failure - July 31, 2015 Category: Cardiology Authors: Sameer Gafoor, Vivek Reddy, Jonathan Halperin, Shephal Doshi, Maurice Buchbinder, Petr Neuzil, Kenneth Huber, Brian Whisenant, Saibal Kar, Vijay Swarup, Mathew J. Price, David Holmes, Nicole Gordon, Horst Sievert Tags: Electrophysiology/Arrhythmias II Source Type: research
Net Clinical Benefit for Oral Anticoagulation, Aspirin, or No Therapy in Nonvalvular Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA 2 DS 2 -VASc Score (Beyond Sex)
Whether to anticoagulate patients with atrial fibrillation (AF) and 1 stroke risk factor (i.e., CHA2DS2-VASc [congestive heart failure, hypertension, age>75 years, diabetes mellitus, stroke, vascular disease, age 65–75 years, and female sex] score = 1 in men, or 2 in women) is controversial, but many studies report ischemic stroke rates of>1.5% per year, even with 1 stroke risk factor (1). We estimated the net clinical benefit (NCB) of aspirin or warfarin compared with no antithrombotic therapy among such patients on the basis of a nationwide Danish cohort, with incident AF diagnosed between 1998 and 2012 (2). Men w...
Source: Journal of the American College of Cardiology - July 20, 2015 Category: Cardiology Source Type: research
Safety and efficacy of transcatheter left atrial appendage closure using the Watchman device in Egyptian patients with nonvalvular atrial fibrillation
Conclusion LAA closure with the Watchman device can be safely performed, and may be a reasonable alternative to consider for patients at high risk for stroke but with contraindications to systemic oral anticoagulation or with high risk of bleeding.
Source: The Egyptian Heart Journal - July 18, 2015 Category: Cardiology Source Type: research
Left Atrial Appendage Closure Is Preferred to Chronic Warfarin Therapy
Publication date: Available online 10 July 2015 Source:Cardiac Electrophysiology Clinics Author(s): Moustapha Atoui, Sampath Gunda, Dhanunjaya LakkireddyTeaser Atrial fibrillation (AF) is associated with increased rates of death, stroke, heart failure, hospitalization, degraded quality of life, reduced exercise capacity, and left ventricular dysfunction. An oral anticoagulant reduces the risk of stroke; however, it places the patient at risk for bleeding complications. Weighing the stroke and bleeding risks remains the key for optimal treatment. Cardiac interventions that can obviate long-term oral anticoagulation hol...
Source: Cardiac Electrophysiology Clinics - July 16, 2015 Category: Cardiology Source Type: research
Stroke prevention in atrial fibrillation: evidence from real-life studies
Atrial fibrillation (AF) is an increasing public health issue, especially owing to an accompanying five-fold increased risk of stroke. Anticoagulants are the cornerstone of therapy for stroke prevention in AF. The clinical benefits of vitamin K antagonists (VKAs; namely warfarin) shown in randomized controlled trials (RCTs) have been challenged when used in clinical practice by issues including the need for international normalized ratio (INR) monitoring, food and drug interactions, low time in the therapeutic range in substantial numbers of patients, and serious bleeding events. Combined, these have led to both an under-i...
Source: European Journal of Heart Failure Supplements - July 10, 2015 Category: Cardiology Authors: Akao, M., Beyer-Westendorf, J., Goto, S., Peterson, E. Tags: Articles Source Type: research
